Hotchkis & Wiley Capital Management
TARO

Hotchkis & Wiley Capital Management’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Hotchkis & Wiley Capital Management’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-223,542
Closed -$8.48M – 543
2023
Q2 		$8.48M Sell
223,542
-60,540
-21% -$1.9M 0.03% 226
2023
Q1 		$6.91M Buy
284,082
+4,700
+2% +$137K 0.03% 281
2022
Q4 		$8.11M Buy
279,382
+40,870
+17% +$1.21M 0.03% 213
2022
Q3 		$7.15M Buy
238,512
+18,020
+8% +$621K 0.03% 209
2022
Q2 		$7.97M Buy
220,492
+28,672
+15% +$1.09M 0.03% 218
2022
Q1 		$8.3M Buy
191,820
+34,795
+22% +$1.63M 0.03% 230
2021
Q4 		$7.87M Buy
157,025
+21,670
+16% +$1.21M 0.02% 233
2021
Q3 		$8.61M Buy
135,355
+7,470
+6% +$517K 0.03% 191
2021
Q2 		$9.2M Buy
127,885
+18,340
+17% +$1.35M 0.03% 193
2021
Q1 		$8.08M Buy
109,545
+8,555
+8% +$650K 0.02% 210
2020
Q4 		$7.42M Buy
100,990
+16,790
+20% +$1.08M 0.03% 146
2020
Q3 		$4.62M Buy
84,200
+16,950
+25% +$1.05M 0.02% 205
2020
Q2 		$4.47M Sell
67,250
-4,270
-6% -$286K 0.02% 213
2020
Q1 		$4.38M Sell
71,520
-4,690
-6% -$348K 0.02% 167
2019
Q4 		$6.7M Buy
76,210
+9,210
+14% +$777K 0.02% 219
2019
Q3 		$5.05M Buy
67,000
+3,050
+5% +$248K 0.02% 220
2019
Q2 		$5.46M Buy
63,950
+6,620
+12% +$655K 0.02% 216
2019
Q1 		$6.2M Buy
+57,330
New +$5.71M 0.02% 141
2016
Q3 		– Sell
-151,330
Closed -$22M – 188
2016
Q2 		$22M Buy
151,330
+2,347
+2% +$333K 0.09% 119
2016
Q1 		$21.3M Buy
148,983
+12,250
+9% +$1.74M 0.09% 118
2015
Q4 		$21.1M Buy
136,733
+5,809
+4% +$848K 0.09% 130
2015
Q3 		$18.7M Sell
130,924
-8,020
-6% -$1.12M 0.07% 135
2015
Q2 		$20M Sell
138,944
-68,214
-33% -$9.73M 0.07% 145
2015
Q1 		$29.2M Sell
207,158
-4,341
-2% -$668K 0.1% 137
2014
Q4 		$31.3M Sell
211,499
-63,565
-23% -$9.34M 0.11% 135
2014
Q3 		$42.3M Sell
275,064
-235,888
-46% -$35.5M 0.15% 111
2014
Q2 		$71.7M Buy
510,952
+55,700
+12% +$6.18M 0.25% 89
2014
Q1 		$50.5M Sell
455,252
-74,684
-14% -$8.13M 0.19% 100
2013
Q4 		$52.4M Buy
529,936
+91,261
+21% +$7.91M 0.22% 88
2013
Q3 		$33.3M Buy
+438,675
New +$28.5M 0.15% 102

Other funds holding TARO

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

Hotchkis & Wiley Capital Management's TARO Position: Q3 2023 in Review

Hotchkis & Wiley Capital Management sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q3 2023, closing a stake of 223,542 shares — an estimated $8.48M sold.

Hotchkis & Wiley Capital Management first reported a position in TARO in Q3 2013 and held it in 30 quarters. The position peaked at $71.7M in Q2 2014. 82 funds tracked by Wall St. Rank hold TARO as of Q3 2023.

  • Hotchkis & Wiley Capital Management reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q3 2023 after selling out during the quarter.
  • Hotchkis & Wiley Capital Management sold 223,542 Taro Pharmaceutical Industries Ltd. shares in Q3 2023, an estimated $8.48M.
  • Hotchkis & Wiley Capital Management first reported a position in Taro Pharmaceutical Industries Ltd. in Q3 2013 and held it in 30 quarters.
  • Hotchkis & Wiley Capital Management's Taro Pharmaceutical Industries Ltd. position peaked at $71.7M in Q2 2014.
  • 82 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q3 2023.

Based on Hotchkis & Wiley Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.